A detailed history of Bridgeway Capital Management, LLC transactions in Scynexis Inc stock. As of the latest transaction made, Bridgeway Capital Management, LLC holds 422,846 shares of SCYX stock, worth $422,846. This represents 0.01% of its overall portfolio holdings.

Number of Shares
422,846
Previous 372,754 13.44%
Holding current value
$422,846
Previous $745,000 15.44%
% of portfolio
0.01%
Previous 0.02%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1.27 - $2.23 $63,616 - $111,705
50,092 Added 13.44%
422,846 $630,000
Q2 2024

Aug 14, 2024

SELL
$1.4 - $2.77 $32,423 - $64,153
-23,160 Reduced 5.85%
372,754 $745,000
Q1 2024

May 15, 2024

BUY
$1.39 - $2.21 $174,792 - $277,907
125,750 Added 46.55%
395,914 $581,000
Q4 2023

Feb 14, 2024

BUY
$1.56 - $2.24 $302,115 - $433,807
193,664 Added 253.16%
270,164 $602,000
Q2 2023

Aug 14, 2023

SELL
$2.38 - $3.67 $58,310 - $89,915
-24,500 Reduced 24.26%
76,500 $225,000
Q1 2023

May 15, 2023

SELL
$1.15 - $3.0 $57,499 - $150,000
-50,000 Reduced 33.11%
101,000 $303,000
Q2 2022

Aug 15, 2022

BUY
$1.77 - $3.87 $131,865 - $288,315
74,500 Added 97.39%
151,000 $281,000
Q3 2021

Nov 15, 2021

SELL
$5.3 - $7.89 $132,500 - $197,250
-25,000 Reduced 24.63%
76,500 $405,000
Q2 2021

Aug 16, 2021

BUY
$6.5 - $9.97 $422,500 - $648,050
65,000 Added 178.08%
101,500 $747,000
Q1 2021

May 17, 2021

BUY
$6.93 - $9.63 $48,510 - $67,410
7,000 Added 23.73%
36,500 $290,000
Q4 2020

Feb 16, 2021

SELL
$4.28 - $7.87 $107,000 - $196,750
-25,000 Reduced 45.87%
29,500 $226,000
Q3 2020

Nov 16, 2020

BUY
$4.37 - $7.48 $238,165 - $407,660
54,500 New
54,500 $240,000

Others Institutions Holding SCYX

About SCYNEXIS INC


  • Ticker SCYX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 32,651,800
  • Market Cap $32.7M
  • Description
  • SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of vario...
More about SCYX
Track This Portfolio

Track Bridgeway Capital Management, LLC Portfolio

Follow Bridgeway Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bridgeway Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Bridgeway Capital Management, LLC with notifications on news.